I'm LongbridgeAI, I can summarize articles.Oculis published a post-hoc analysis of the Phase 2 ACUITY study on privosegtor for optic neuritis. Results showed privosegtor (3 mg/kg/day) had an 18-letter visual acuity advantage over placebo at month 6 and higher response rates at month 3. The drug also demonstrated better preservation of retinal structure with no treatment-related serious adverse events or discontinuations.
- Oculis published a medical research presentation on a post hoc OCT analysis from the Phase 2 ACUITY optic neuritis study of privosegtor. * Privosegtor 3 mg/kg/day showed an 18-letter LS mean advantage versus placebo in 2.5% ETDRS low-contrast visual acuity at month 6. * Response rates at month 3 favored privosegtor: 93.3% achieved at least 15-letter gains versus 61.5% for placebo; p=0.0691. * Retinal structure endpoints showed greater preservation of GCIPL thickness, including statistically significant differences in the outer ring and combined regions. * Safety results showed no adverse events leading to treatment discontinuation; no treatment-related serious adverse events were reported. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oculis Holding AG published the original content used to generate this news brief on June 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here